- Home
- ARDX
ARDX
Ardelyx Inc.
as 01-21-2025 4:00pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.2B | IPO Year: | 2014 |
| Target Price: | $10.58 | AVG Volume (30 days): | 5.0M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $10.13 | Next Earning Date: | 02-20-2025 |
| Revenue: | $251,849,000 | Revenue Growth: | 87.57% |
| Revenue Growth (this year): | 168.07% | Revenue Growth (next year): | 16.66% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Jan 7 '25 | Sell | $5.31 | 41,666 | $221,308.96 | 1,129,552 | |
| MOTT DAVID M | ARDX | Director | Dec 19 '24 | Buy | $4.67 | 213,300 | $996,580.26 | 1,638,765 | |
| RAAB MICHAEL | ARDX | President & CEO | Dec 10 '24 | Sell | $5.26 | 25,000 | $131,620.00 | 1,129,552 | |
| RAAB MICHAEL | ARDX | President & CEO | Nov 25 '24 | Sell | $5.38 | 25,000 | $134,482.50 | 1,129,552 | |
| RAAB MICHAEL | ARDX | President & CEO | Nov 20 '24 | Sell | $4.79 | 31,980 | $153,328.11 | 1,129,552 | |
| Rosenbaum David P. | ARDX | Chief Development Officer | Nov 20 '24 | Sell | $4.79 | 7,184 | $34,443.69 | 297,005 | |
| Renz Justin A | ARDX | Chief Financial Officer | Nov 20 '24 | Sell | $4.79 | 5,260 | $25,219.07 | 291,139 | |
| Williams Laura A | ARDX | Chief Medical Officer | Nov 20 '24 | Sell | $4.79 | 7,366 | $35,316.29 | 308,745 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Nov 20 '24 | Sell | $4.79 | 7,046 | $33,782.05 | 185,334 | |
| Blanks Robert | ARDX | See Remarks | Nov 20 '24 | Sell | $4.79 | 4,941 | $23,689.62 | 314,421 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
GlobeNewswire
9 days ago
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
GlobeNewswire
16 days ago
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
23 days ago
Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?
Simply Wall St.
23 days ago
Exploring 3 High Growth Tech Stocks in the United States
Simply Wall St.
a month ago
US Penny Stocks To Watch In December 2024
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 12/27/2024
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 12/26/2024
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.